Literature DB >> 8232220

Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.

Z Abdel-Razzak1, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune, A Guillouzo.   

Abstract

Cytokines are thought to cause the depression of cytochrome P-450 (CYP)-associated drug metabolism in humans during inflammation and infection. We have examined the role of five cytokines, i.e., interleukin-1 beta, interleukin-4, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma, on the expression of CYP1A2, CYP2C, CYP2E1, CYP3A, and epoxide hydrolase in primary human hepatocyte cultures. Steady state P-450 and epoxide hydrolase mRNA levels, as well as ethoxyresorufin-O-deethylase and nifedipine oxidation activities, which are mainly supported by CYP1A1/1A2 and CYP3A, respectively, were measured. Interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha were found to be the most potent depressors of P-450 enzymes. After 3 days of treatment, both mRNA levels and enzyme activities were depressed, typically by at least 40%, whatever the cytokine and the enzyme considered. Interferon-gamma also suppressed CYP1A2 and CYP2E1 mRNA levels and ethoxyresorufin-O-deethylase activity but had no effect on CYP3A and epoxide hydrolase mRNAs. In addition, interleukin-4 had the opposite effect, compared with other cytokines, on CYP2E1 mRNA, which was increased up to 5-fold; ethoxyresorufin-O-deethylase and nifedipine oxidation activities were not significantly affected. These results provide the first demonstration that various cytokines act directly on human hepatocytes to affect expression of major P-450 genes and that a wide range of responses can be observed among the enzymes for a given cytokine, suggesting that different regulatory mechanisms may be involved.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232220

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  108 in total

Review 1.  Vaccine-Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms.

Authors:  Paolo Pellegrino; Cristiana Perrotta; Emilio Clementi; Sonia Radice
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

2.  Increased oxidative DNA damage and hepatocyte overexpression of specific cytochrome P450 isoforms in hepatitis of mice infected with Helicobacter hepaticus.

Authors:  M A Sipowicz; P Chomarat; B A Diwan; M A Anver; Y C Awasthi; J M Ward; J M Rice; K S Kasprzak; C P Wild; L M Anderson
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

Review 3.  Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors:  Iftekhar Mahmood; Martin D Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.

Authors:  Sebastian Trousil; Patrizia Lee; Robert J Edwards; Lynn Maslen; Jingky P Lozan-Kuehne; Ramya Ramaswami; Eric O Aboagye; Stephen Clarke; Christopher Liddle; Rohini Sharma
Journal:  Br J Pharmacol       Date:  2019-08-05       Impact factor: 8.739

5.  Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.

Authors:  Amélie Moreau; Marc Le Vée; Elodie Jouan; Claire Denizot; Yannick Parmentier; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 6.  Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily.

Authors:  Tomas Smutny; Sridhar Mani; Petr Pavek
Journal:  Curr Drug Metab       Date:  2013-12       Impact factor: 3.731

7.  Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Authors:  Alison E Aitken; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

8.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart.

Authors:  Saeed Sattari; William F Dryden; Lise A Eliot; Fakhreddin Jamali
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices.

Authors:  Hélène Martin; Jean-Pierre Sarsat; Isabelle de Waziers; Chantal Housset; Pierre Balladur; Philippe Beaune; Véronique Albaladejo; Carole Lerche-Langrand
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.